论文部分内容阅读
目的:观察舒肝解郁胶囊联合莫沙比利治疗功能性消化不良的临床疗效。方法:选择存在焦虑和(或)抑郁的65例功能性消化不良患者,随机分为2组,治疗组33例服用舒肝解郁胶囊联合枸橼酸莫沙比利分散片,对照组32例仅服用枸橼酸莫沙比利分散片。分别于治疗前后评价患者的症状以及采用汉密尔顿抑郁量表(HAMD)和汉密尔顿焦虑量表(HAMA)进行心理测评。结果:治疗组餐后饱胀不适、早饱感、上腹痛、上腹烧灼感的疗效总有效率均高于对照组,差异均有统计学意义(P<0.05,P<0.01)。治疗组治疗后与随访的HAMD积分、HAMA积分均较治疗前下降,差异均有统计学意义(P<0.05);与同期对照组比较,差异均有统计学意义(P<0.05);对照组2项积分未见明显变化,治疗后、随访与治疗前分别比较,差异均无统计学意义(P>0.05)。结论:采用舒肝解郁胶囊联合莫沙比利治疗功能性消化不良,不仅能够显著改善患者的焦虑和(或)抑郁状态,而且在症状缓解方面优于单纯口服莫沙必利,疗效显著。
Objective: To observe the clinical efficacy of Shugan Jieyu capsule combined with Mosapride in the treatment of functional dyspepsia. Methods: Sixty-five patients with functional dyspepsia who had anxiety and / or depression were randomly divided into two groups. The treatment group received Shugan Jieyu capsules combined with mosapride citrate dispersible tablets and the control group, 32 patients Only taking mosapride citrate dispersible tablets. Patients’ symptoms were assessed before and after treatment, and psychological tests were performed using Hamilton Depression Rating Scale (HAMD) and Hamilton Anxiety Scale (HAMA). Results: The total effective rate of full-discomfort post-prandial diet, early-full-feeling, upper-abdominal pain and upper abdominal burning sensation in the treatment group were all higher than those in the control group, with statistical significance (P <0.05, P <0.01). The HAMD score and HAMA score of the treatment group after treatment were lower than those before treatment (P <0.05), and there were significant differences between the treatment group and the control group (P <0.05). The control group There was no significant difference between the two items. After treatment, there was no significant difference between the follow-up and before treatment (P> 0.05). Conclusion: Shugan Jieyu capsules combined with mosapride in patients with functional dyspepsia not only can significantly improve the patient ’s anxiety and / or depression, but also in the symptom relief than simple oral mosapride, a significant effect.